RELMADA THERAPEUTICS, INC.: 10-Q filed 2022-05-05
What RELMADA THERAPEUTICS, INC. reported in its quarterly report filed 2022-05-05 (fiscal Q1 2022): 28 published measures, 56 facts as tagged in accession 0001213900-22-024229.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2022-05-05
- Fiscal period
- fiscal Q1 2022
- Accession
- 0001213900-22-024229 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All RELMADA THERAPEUTICS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 225,807,609 | USD | |
| At 2021-12-31 | 223,325,811 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 15,409,477 | USD | |
| At 2021-12-31 | 15,060,925 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 210,398,132 | USD | |
| At 2021-12-31 | 208,264,886 | USD | |
| At 2021-03-31 | 91,147,128 | USD | |
| At 2020-12-31 | 105,582,746 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | -39,745,783 | USD | 90 |
| 2021-01-01 to 2021-03-31 | -22,215,181 | USD | 90 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | -19,429,743 | USD | 90 |
| 2021-01-01 to 2021-03-31 | -16,085,475 | USD | 90 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 29,948,348 | USD | 90 |
| 2021-01-01 to 2021-03-31 | 1,928,279 | USD | 90 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | -10,027,668 | USD | 90 |
| 2021-01-01 to 2021-03-31 | 15,465,841 | USD | 90 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | -344,812,895 | USD | |
| At 2021-12-31 | -305,067,112 | USD |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 28,392,601 | shares | 90 |
| 2021-01-01 to 2021-03-31 | 16,572,672 | shares | 90 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | -1.4 | USD/shares | 90 |
| 2021-01-01 to 2021-03-31 | -1.34 | USD/shares | 90 |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 11,930,681 | USD | 90 |
| 2021-01-01 to 2021-03-31 | 5,851,284 | USD | 90 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | -38,297,423 | USD | 90 |
| 2021-01-01 to 2021-03-31 | -22,405,203 | USD | 90 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 225,779,316 | USD | |
| At 2021-12-31 | 223,297,518 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 15,409,477 | USD | |
| At 2021-12-31 | 15,060,925 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 10,670,149 | USD | |
| At 2021-12-31 | 11,192,502 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 38,297,423 | USD | 90 |
| 2021-01-01 to 2021-03-31 | 22,405,203 | USD | 90 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 25,012,853 | USD | 90 |
| 2021-01-01 to 2021-03-31 | 14,022,227 | USD | 90 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 29,402,824 | shares | |
| At 2021-12-31 | 27,740,147 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 555,181,624 | USD | |
| At 2021-12-31 | 513,304,258 | USD |
Total equity including noncontrolling interests
Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 210,398,132 | USD | |
| At 2021-12-31 | 208,264,886 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 28,293 | USD | |
| At 2021-12-31 | 28,293 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 4,739,328 | USD | |
| At 2021-12-31 | 3,868,423 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | -39,745,783 | USD | 90 |
| 2021-01-01 to 2021-03-31 | -22,215,181 | USD | 90 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 13,284,570 | USD | 90 |
| 2021-01-01 to 2021-03-31 | 8,382,976 | USD | 90 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | 806 | USD | 90 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | -1,448,360 | USD | 90 |
| 2021-01-01 to 2021-03-31 | 190,022 | USD | 90 |
Proceeds from issuing common stock
Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 29,583,542 | USD | 90 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | -522,353 | USD | 90 |
| 2021-01-01 to 2021-03-31 | -263,679 | USD | 90 |
Inspect the source
- Entity
- RELMADA THERAPEUTICS, INC. / CIK 0001553643
- Captured
- 2026-09-19T11:18:56.464Z
- SEC response SHA-256
34acb6579adb694402af1f940d83014f7841c8cf763b03e27ee64d386466bb53
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001553643.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))